Evotec SE and Novo Nordisk today announced LAB eN² (pronounced Lab ee – en – squared), a translational drug discovery accelerator that aims to nurture early research from academic institutions into novel therapeutics. The focus is on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders.
↧